Atossa Genetics, which develops diagnostic tests and treatments for breast cancer, raised $4 million by offering 800,000 shares at $5, the midpoint of the range of $4 to $6. Atossa Genetics plans to list on the NASDAQ under the symbol ATOS. Dawson James acted as the sole bookrunner on the deal.
